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Scaffold Translation: Barriers Between Concept and Clinic
Scott J. Hollister, Ph.D.,1 and William L. Murphy, Ph.D.2
Translation of scaffold-based bone tissue engineering (BTE) therapies to clinical use remains, bluntly, a failure.
This dearth of translated tissue engineering therapies (including scaffolds) remains despite 25 years of re-
search, research funding totaling hundreds of millions of dollars, over 12,000 papers on BTE and over 2000
papers on BTE scaffolds alone in the past 10 years (PubMed search). Enabling scaffold translation requires first
an understanding of the challenges, and second, addressing the complete range of these challenges. There are
the obvious technical challenges of designing, manufacturing, and functionalizing scaffolds to fill the Form,
Fixation, Function, and Formation needs of bone defect repair. However, these technical solutions should be
targeted to specific clinical indications (e.g., mandibular defects, spine fusion, long bone defects, etc.). Further,
technical solutions should also address business challenges, including the need to obtain regulatory approval,
meet specific market needs, and obtain private investment to develop products, again for specific clinical
indications. Finally, these business and technical challenges present a much different model than the typical
research paradigm, presenting the field with philosophical challenges in terms of publishing and funding
priorities that should be addressed as well. In this article, we review in detail the technical, business, and
philosophical barriers of translating scaffolds from Concept to Clinic. We argue that envisioning and engi-
neering scaffolds as modular systems with a sliding scale of complexity offers the best path to addressing these
translational challenges.
Introduction
Rembrandt Harmenszoon van Rijn (1606–1669) wasperhaps the greatest painter of self-portraits in history,
and left a chronology of his life from a young artist in 1630
(Self-Portrait with Wide-open Eyes, Amsterdam, the Rijks-
museum), through his middle-aged years (1659, Self-Portrait
with Beret and Turned Up Collar, National Gallery of Art,
Washington, DC), to a portrait finished before his death in
1669 (Self-Portrait, London, the National Gallery).1 These
self-portraits depict the artist aging in detail, reflecting the
many trials that Rembrandt faced in his life.
Review papers are, in essence, a self-portrait of a field, and
similar to the self-portraits of Rembrandt, should provide an
honest appraisal of a field’s current status, its trials, and its
prospects. Our purpose in this article is to describe the cur-
rent status of bone tissue scaffold engineering relative to
clinical translation. As such, although we will review some
technical advances in bone tissue scaffolding, our main in-
terest is to detail the barriers to scaffold translation, how
current work in the field stacks up against these barriers, and
how adaptation of modular engineering may help mitigate
these barriers.
We cannot characterize the barriers to, and current state
of, scaffold translation, until we first define the goal of bone
tissue engineering (BTE) and the role that scaffolds play in
attaining this goal. The goal of BTE is to develop viable,
clinically competitive approaches for bone reconstruction in
Orthopedic, Spine, and CranioMaxilloFacial (CMF) surgery.
Clinically competitive implies that a tissue engineering
therapy provides one or more of the following: (1) improved
patient outcomes, (2) reduced morbidity or complication
(e.g., by eliminating the need to harvest bone graft), or (3)
reduced procedural expense (e.g., through reduced operating
time or patient hospitalization stay). Relative to this defined
goal, BTE, and by extension BTE scaffolds, has been, to date,
a failure.
What is the basis for this blunt statement? First, as ex-
tensively noted by Ratcliffe,2,3 the number of combination
BTE products can be counted on one hand. These include
degradable bone void fillers, which can be considered as BTE
scaffolds, combined with biologics. Recombinant human
bone morphogenetic protein 2 (rhBMP2) has been the most
commercially successful BTE product, being utilized in up to
25% of all spinal fusion procedures,4 and a variety of off-
label applications (up to 83% of rhBMP2 use has been
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estimated to be off label5). However, there have also been
significant complications with rhBMP2 use, including patient
death, dysphagia, and airway compression in cervical spine
fusion,6–10 heterotopic bone formation in the spinal canal11–14
causing the U.S. Food and Drug Administration (FDA) to
halt one posterior lateral fusion (PLF) clinical study, hetero-
topic bone formation in tibial fracture repair,15 and retro-
grade ejaculation in patients undergoing anterior lumbar
interbody spine fusion.16 In addition, the FDA recently re-
jected the Medtronic AMPLIFY product using rhBMP2 with
a composite collagen I/beta-tri-calcium phosphate (b-TCP)/
hydroxyapatite (HAP) carrier for PLF product citing con-
cerns about cancer risk in the BMP2 group versus the control
group.17 Further, there are significant questions concerning
whether rhBMP2 provides better outcomes,4 and even if so,
these numbers indicate that 75% of spine fusions are still
done by using traditional bone grafting methods.
For complex, large defects (especially in CMF reconstruc-
tion), the clinical gold standard remains the vascularized
free-fibular graft,18–21 and indeed, no surgeon would con-
sider using a BTE alternative, as none exist. Simply stated,
there are very limited numbers of BTE clinical products, and
bone grafting (auto or allo) remains the overwhelming
treatment of choice. Thus, BTE has failed to achieve the goal
of becoming a viable clinical alternative, despite 25 years of
research, hundreds of millions of dollars of federal research
funding in the United States by both the National Institutes
of Health (NIH) and United States Department of Defense
(DOD, including the Armed Forces Institutes of Regenerative
Medicine [AFIRM]), and over 12,000 papers published on
BTE in the last 10 years, including over 2000 papers on BTE
scaffolds. Understanding why scaffold-based BTE has failed
to date as a viable clinical alternative for bone reconstruction
requires a detailed overview of the technical, business and
philosophical barriers to translation.
Technical Barriers to Scaffold Translation
The first barrier to scaffold translation is addressing all the
technical demands that a scaffold should fulfill to success-
fully reconstruct bone defects. In this sense, the technical
demands are analogous to the necessary part of the neces-
sary and sufficient conditions for a logical proof. It is nec-
essary that technical demands be met, but meeting technical
demands is far from sufficient to make a scaffold successful,
as noted in the subsequent sections.
To address technical demands, we should first identify
these demands and then specify quantitative targets that
need to be met to satisfy these demands. This is not only
good engineering practice, but also required by the FDA as a
part of the Design History File and Device History File for
current Good Manufacturing Practices (cGMP). Technical
scaffold demands can be qualitatively summarized as the
4Fs: Form, Function, Fixation, and Formation.22 Form is the
requirement that scaffolds fill complex three-dimensional
(3D) bone defects. Function is the requirement that scaffolds
provide temporary mechanical load bearing within bone
defects. Fixation is the requirement that scaffolds are se-
curely attached to bone at the defect margins, eliminating
motion between host bone and scaffold that could lead to
nonunion and pseudarthrosis. Formation is the requirement
that scaffolds enhance bone formation by providing appro-
priate mass transport environments, allowing perfusion, and
delivering osteoinductive factors, including cells, proteins,
and/or genes.
To drive engineering and material design, however (and
satisfy Design History requirements for cGMP), we should
define quantitative requirements associated with the 4Fs.
Form is readily identified by the 3D defect geometry defined
on computed tomography or magnetic resonance images.
However, complex 3D defect geometry will typically have to
be characterized by using 3D design data such as triangular
surface facets or polylines, and require specific image pro-
cessing and Computer Aided Design software. Generation
of. STL data allows computational definition of defect space,
specifically characterization of defect geometry in terms of
volume and surface area. Function implies that the scaffold
can withstand stresses under loading without failure or ex-
cess deformation. Since anatomic loading conditions are
notoriously difficult to specify, scaffold mechanical design
requirements have been simplified to match some fraction of
native bone linear elastic properties,23–26 which have been
extensively detailed.27–31 Fixation requirements are also
mechanical, specifically requiring that motion at the scaf-
fold/native bone interface be minimized32–36 (strain < 2%–
3%36) to avoid pseudarthrosis.
Of the 4Fs, quantitative requirements governing forma-
tion are the most nebulous and difficult to specify. There are
two general, yet coupled, scaffold attributes that influence
bone regeneration. The first is mass transport and perfu-
sion, which is dictated by 3D scaffold pore architecture. The
second is delivery of biologics including cells, proteins,
and/or genes that promote bone formation. The two are
coupled, as the 3D pore architecture determines the nutrient/
waste diffusion to seeded cells, provides a migration path for
host cells, and determines the 3D distribution of proteins and
genes and their interaction with cells as delivered from the
scaffold. Mass transport can be quantitatively characterized
by permeability, which relates fluid velocity in a porous
medium to the pressure gradient, and diffusivity, which re-
lates ion concentration to chemical concentration gradients.
Biologic delivery is much more difficult to quantitatively
define, and it depends on biologic-scaffold interactions and
scaffold degradation, as well as on mass transport.
Creating a scaffold to address all the 4F quantitative re-
quirements is an extremely challenging task, and may be
implausible in some clinical applications. It is complicated
by a number of factors, including (1) we don’t know the
target values for most of the quantitative design require-
ments (elastic properties, permeability, diffusivity, surface
area, etc), (2) to establish design target values, we should be
able to engineer scaffolds with controlled ranges of these
properties to test design hypotheses,26 and (3) these prop-
erties occur on multiple, interrelated hierarchical scales.
Engineering scaffolds with controlled properties at hierar-
chical scales require (1) computational design methods that
can represent geometry and compute effective properties
(elasticity, permeability, diffusion, degradation, etc.) based
on hierarchical material and pore distribution, and (2) fab-
rication methods that can build scaffolds with integrated
biologics at multiple scales from multiple materials. It is
difficult, if not impossible at the moment, for any compu-
tational design or fabrication technology to address all
scales. Therefore, both the computational design and
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fabrication are broken into separate, but more weakly
connected, pieces or modules, at different hierarchical
scales. This concept of separating both design and fabrica-
tion into loosely connected modules is aptly named
‘‘modularity.’’ Modularity has been employed for a num-
ber of years for design and manufacturing in the com-
puter industry,37 but beyond this is seen as the basis of
creating complex systems in technology38 and even in
nature.39–41
Hierarchical modularity in design entails computing ef-
fective properties (elasticity, permeability, diffusivity, and
degradation) to meet functional and formation requirements
by distribution of material and pore structures at multiple
levels in 3D space. Homogenization theory42,43 has been
adopted by our group44,45 and others46,47 to compute effec-
tive scaffold and biologic tissue properties directly from 3D
hierarchical morphology and scaffold architecture. In addi-
tion, homogenization theories have been used within topol-
ogy optimization schemes48,49 by our group50–53 and
others54,55 to actually predict the optimal scaffold architec-
ture that will give desired effective properties. Homo-
genization theory is an asymptotic expansion of partial
differential equations that allows separation of scales. This
theory assumes that a global macroscopic structure (the an-
atomic scaffold) is made of repeating periodic unit cells (in
this case, cell refers to a mathematical unit). Thus, periodic
unit cells provide a natural modularity to design in that each
spatial location can be separately designed.
The controlled 3D pore architecture created by periodic
unit cell design within an already complex anatomic defect56
cannot readily be manufactured from even a single-phase
material at one scale. Creating scaffolds having controlled
architectures with multiple scales, multiple materials, and
delivering multiple biologics (including seeded cells) is vir-
tually impossible with a single-step fabrication process. In-
stead, multiple, sequential fabrication steps can be linked
together to create a scaffold with multiple scales, functiona-
lized with multiple biologics. Fabricating scaffolds with
complex, anatomic shape integrated with rigorously con-
trolled 3D pore architecture cannot be accomplished with
more traditional techniques such as porogen leaching, gas
foaming, electrospinning, or emulsion (see e.g., Refs.57–64).
Solid free-form fabrication (SFF) techniques are the most
viable technology for fabricating scaffolds with complex
anatomic shape integrated with controlled 3D pore archi-
tecture. Indeed, since the first application of SFF to scaf-
folding in the late 1990s,65,66 there has been a explosion of
scaffold SFF with applications ranging from cell culture to
large preclinical animal models to human patients.67–104
However, SFF is typically limited in terms of feature size
resolution to the hundreds of micron scale. Again, modu-
larity comes into play when the traditional scaffold fabrica-
tion techniques can be combined with SFF to fabricate
hierarchical scaffolds,100,105 or to create bioactive scaffolds
with controlled architecture by linking biologics to SFF
scaffolds.106–109
Modularity can be used to promote bone formation
within scaffolds without negatively impacting form, func-
tion, and fixation. There is a common trade-off between the
4Fs during scaffold design, as strategies to promote for-
mation can require manufacturing techniques or base ma-
terials that intrinsically limit scaffold physical properties
that relate to form, function, and fixation. Perhaps the most
extreme example are collagen-based scaffolds, which have
biological properties that can be attractive for bone forma-
tion, but have elastic moduli orders of magnitude lower
than native bone tissue. Modular strategies can be used to
design physically robust scaffolds that promote bone for-
mation by taking advantage of key scaffold parameters.
One such parameter is pore size, as recent studies demon-
strate that microporous materials can promote enhanced
bone ingrowth when compared with nonmicroporous ma-
terials.110–113 Another key parameter is ‘‘osteoconductivity’’
provided by calcium phosphate (CaP)-based minerals. CaP
materials have been widely used as bone substitutes in
dentistry and orthopedics, as they bear compositional and
functional similarity to human teeth and bones.114 Common
clinical examples of CaP materials include hydroxyapatite
(HAP, Ca10(PO4)6(OH)2), b-TCP (b-Ca3(PO4)2), and biphasic
CaP composed of HAP and b-TCP. CaP materials are os-
teoconductive in that they improve integration of bioma-
terials with surrounding bone tissue, and further serve as a
template for the proper function of bone-forming cells. The
favorable aspects of CaP materials have led to their exten-
sive clinical use as bone void fillers,115 and as coating ma-
terials on various implants to promote bone-implant
bonding,116 and a subset of studies have indicated that CaP
scaffolds can also be osteoinductive at heterotopic sites in
some animal models.117 Another set of recent studies has
demonstrated that ions (e.g., strontium, zinc) incorporated
into Ca-based materials can induce bone formation by ac-
tivating pro-osteogenic gene expression.118,119 Each of these
previous studies describe bone formation parameters that
can be used for scaffold design, and, importantly, these
parameters can be potentially optimized without negatively
impacting bulk scaffold properties.
There has been a growing demand to deliver biologically
active proteins, such as growth factors, cytokines, and anti-
bodies, which can actively guide cellular response toward
new bone formation. Modularity in the form of sequential
bio-functionalization procedures postfabrication can also be
potentially used to deliver biologics, thus creating bioactive
scaffolds. However, the majority of biologics delivery strat-
egies do not use carriers with appropriate form, function, or
fixation. The common strategy instead involves designing a
biologics ‘‘carrier,’’ then combining the carrier with a stan-
dard orthopedic device with appropriate physical properties.
Notable examples include rhBMP2-loaded or OP-1-loaded
collagen matrices combined with a titanium cage120,121 or
other metallic hardware.122 Innovative biomaterials for con-
trolled release,123 ranging from polymer scaffolds to inject-
able micro- and nanoparticles, are also typically developed in
a manner that requires combination with a structural device.
This ‘‘combination approach’’ presents a challenge in clinical
translation, as there is, in essence, a need to develop two
separate scaffolds—one for delivery and one for appropriate
form, function, and fixation. An alternative ‘‘modular ap-
proach’’ would involve integrating the biologics carrier into
the structural device without negatively impacting physical
properties. In this case, the same basic device platform can be
derivatized with multiple levels of complexity, ranging from
scaffold material alone to scaffold loaded with multiple bi-
ologics. One strategy to achieve scaffold modularity involves
creating surface coatings. Coatings can effectively serve as
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carriers without significantly impacting bulk scaffold prop-
erties, and they can also be designed to impart other desir-
able properties (e.g., osteoconductivity, biocompatibility). In
addition, it is possible to design broadly adaptable surface
coatings for controllable delivery of peptides, proteins, DNA,
cells, and combinations thereof. Our recent experience with
nanostructured mineral coatings that bind to biologics pro-
vides one example of the utility of a modular approach.124–128
We have also developed molecular coatings that can induce
bone formation,108,128–131 and the interaction between the
osteoinductive molecule and the scaffold can be used to
dictate the release rate. In each case, the biologics delivery is
decoupled from device physical properties, thus allowing for
independent optimization of each component in a modular
scaffold.
It is noteworthy that combining biologics with an appro-
priate scaffold is just one of the several inherent challenges in
biologics delivery. Whether the biologic of interest is an os-
teoinductive molecule, gene, or cell, there are a series of
critical technical hurdles to be addressed. First, there are
unique, complex dynamics in each bone defect environment
that make it difficult to define a consistently desirable de-
livery dose and time scale. The integrity of the soft tissue
envelope, status of the periosteum, and age-dependent
abundance of bone-forming cell types are among the vari-
ables that are not normalized across different patient popu-
lations. Second, existing biologics carriers use very high
doses delivered over relatively short timescales, which has
led to well-documented side effects such as edema,4,132 het-
erotopic bone formation,14 and increased cancer risk.16 For
example, the recent Medtronic Investigational Device Ex-
emption (IDE)/investigational new drug application to de-
liver rhBMP2 using the composite collagen/HA/TCP matrix
Amplify noted that up to 20–24mg of rhBMP2 were needed
to obtain fusion in a non-human primate model.133 Why is
there a need to deliver such a large dose of osteoinductive
growth factors? One reason is likely sub-optimal growth
factor release kinetics, which lead to limited activity during
the bone healing process.134 In addition, osteoinductive
growth factors can induce production of their own inhibi-
tors (e.g., BMP2-induced production of noggin), can present
T- and B-cell antigens, and can influence multiple distinct cell
types.135,136 Finally, a recent study indicates that more than
6500 genes are differentially regulated during bone heal-
ing,137 which suggests a molecularly complex environment
in which multiple biologics may be needed to promote op-
timal formation of bone and other supportive tissue types
(e.g., neural, vascular tissues). However, the substantial
barriers to clinically translating single biologics carriers
suggest that carriers for multiple biologics are likely to en-
counter even greater challenges. In view of this complexity,
there is a clear need to develop adaptable scaffolds that can
be used to gain fundamental insights into induced bone
formation in a context which can then be efficiently trans-
lated to clinical applications.
The sequential fabrication/surface modification tech-
niques needed to create modular, adaptable scaffolds ad-
dressing all the 4Fs can be separated into parallel physical
and processing modules. In this sense, very complex bioac-
tive scaffolds can be created by modularity (illustrated in Fig.
1), mimicking the use of modularity in both man-made and
natural applications ranging from aerospace technology to
genetics in creating complex systems from simpler functional
units.37–41 Further, since both design and fabrication in this
modular framework are sequential, scaffold complexity can
essentially be ‘‘dialed in,’’ to custom fit scaffolds for clinical
indications and regulatory requirements, as discussed in the
next section. Modularity also allows for separate im-
plementation of design control and quality processes, sim-
plifying troubleshooting and reducing expenses, which is
essential to making scaffolds practical and cost effective as
viable clinical approaches.
Business Barriers to Scaffold Translation
The business challenges to translation include regulatory
approval, obtaining external funding for product develop-
ment, obtaining physician acceptance, and, in certain cir-
cumstances, obtaining approval for insurance reimbursement.
The common thread running through all these steps is the
need to tailor the scaffold for specific clinical indications or
needs. Although many researchers will perhaps never deal
FIG. 1. Hierarchical, modular con-
cept for scaffold engineering. Sche-
matic illustration of anatomic, three-
dimensional porous architecture, and
biologic design of a scaffold for man-
dibular reconstruction. This scaffold
would be created through sequential
engineering processes in a modular
manner. CaP, calcium phosphate; SFF,
solid free-form fabrication. Color
images available online at www
.liebertonline.com/teb
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with these issues (or have a wish to), anyone interested in
translating their scaffold technology must either face these is-
sues themselves or hand off their technology in the form of
a license to others who must then face these issues. Our
argument is that facing these issues earlier in the research
process within a modular engineering framework makes
achieving downstream translation a smoother process.
The gating item to any commercialization of scaffold
technology is achieving regulatory approval. Regulatory
approval relevant to BTE scaffolds as devices can be broadly
divided into class II (requiring 510K approval) and class III
(requiring an IDE, and if successful leading to Pre-Market
Approval [PMA]). Basically, class II approval will typically
require that laboratory bench tests covering biocompatibility
be performed in addition to relevant mechanical testing. In
addition, an in vivo animal model (typically in rabbits, dogs,
goats, sheep, or pigs) will be required to investigate tissue
response compared with an existing clinical device (termed a
predicate device) that most closely resembles the scaffold for
which approval is sought. There are currently five primary
clinical applications (also termed clinical indications) for BTE
scaffolds that allow approval via a 510K pathway. These are
(1) Bone anchoring/fixation systems,138 (2) General Bone
void filler,139 (3) Cranioplasty (filling skull defects, a spe-
cialized case of General Bone Void Filler), (4) Dental Bone
Void Filler (filling nonload bearing maxilla/mandibular
bone defects, for instance, in ridge augmentation),140 and (5)
Interbody Spinal Fusion devices.141 All these indications
and the necessary tests for regulatory approval are outlined
in the referenced FDA guidance documents. A common
thread running through 510K bone indications is that most
are minimally or nonload bearing (except for spinal fusion
devices), and all indications require testing in an animal
model of size equal to or larger than a rabbit with the
specified bone defect. Although degradable materials such
as tissue engineering scaffolds are commonly approved
under general bone void filler, dental bone void filler, and
cranioplasty indications, the use of degradable materials
for spine fusion may face more rigorous evaluation, to the
point of requiring human clinical data with the 510K sub-
mission in addition to the large preclinical animal model
results.
Beyond these defined indications, or if the scaffold is used
in combination with a drug or biologic such as BMP2 for any
indication, an IDE will be required to test the scaffold in
human clinical trials. These clinical trials are in addition to
similar bench and large preclinical animal trials that are re-
quired for 510K submissions. The clinical trials are split into
phases, with a phase I trial being a small trial with 10–15
patients to demonstrate safety, and a phase II clinical trial
being a larger trial with 100–500 patients to demonstrate
efficacy against the standard of care for the specific clinical
indication. Again, as with 510K submissions, approval is
given to a specific scaffold configuration for a specific clinical
indication, not as a broad brush approval for multiple indi-
cations. Indeed, even though the same type I collagen sponge
carrier was used to deliver BMP2 in each case, separate ap-
proval paths with a different cohort of large animal models
as well as separate clinical trials were required for use in
lumbar spine fusion, tibial nonunions, and sinus/ridge
augmentation (Table 1).
A number of things are readily apparent from Table 1.
First, of course, is that each regulatory submission is targeted
at a very specific clinical indication. Second, the number of
large animals in a given preclinical study is substantial.
Third, the cost of performing the preclinical studies and
human clinical trials is substantial, with Ratcliffe2,3 estimat-
ing between $50 and $300 million over 8–10 years for ap-
proval of a combination product. Of course, despite the
substantial investment needed, the PMA process also offers
no guarantee of success. For example, a recent FDA appli-
cation for use of the Medtronic AMPLIFY rhBMP2 carrier I
posterolateral spine fusion included 463 patients and a 60
months follow-up, but resulted in rejection.17,133
In addition to the experimental studies required for reg-
ulatory approval of a given clinical indication, there are
additional requirements to obtain marketing approval.
First, in parallel with the preclinical studies required in a
510K or PMA application, biocompatibility of the base
scaffold material should be established by performing
bench and small animal tests as per International Standards
Organization (ISO) 10993 guidelines. These tests in and of
themselves may cost between $0.5 million and $3 million.
Finally, approval to market a scaffold requires that cGMP to
Table 1. Number of Animals Used to Support Investigational Device Exemption/Pre-Market Approval
Applications for Four Clinical Indications: (1) Lumbar Interbody Spine Fusion, (2) Lumbar
Posterior Lateral Fusion (Not Currently Approved as of July, 2011), (3) Tibial Nonunion,
and (4) Sinus Lift/Ridge Augmentation
Animal model/
indication Dog/Rabbit Goat/Sheep
Non-human
primate
Human-
phase I
Human-
phase II
Lumbar Interbody Fusion 24 15 14 413
Lumbar posterior
lateral fusion
173
45 Dogs/118 Rabbits
50 463
29 clinical sites
Tibial nonunion 175
48 Dogs/127 Rabbits
22
12 Goats/
10 Sheep
42 299
Sinus Lift/Ridge
augmentation
16 Studies; Estimate:
60–120 animals
8 Studies; Estimate:
30–60 animals
208 Sinus Lift; 80
Ridge Augmentation
Note that for the fourth indication, only the number of animal studies and experimental groups were provided, and the total number of
animals was estimated by assuming four to eight animals per experimental group.
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mass produce the scaffold is in place. The cGMP consists of
two primary phases. The first is a Design History file, in
which the scaffold design characteristics are detailed, in-
cluding material, geometry, porosity, mechanical proper-
ties, and so on. In this file, the acceptable ranges for these
parameters are given, in addition to the tests that will be
used to determine whether the actual scaffold device meets
the design criteria. The second is the Device History file, in
which the history of actual manufactured scaffolds are
traced, including the outcome of tests to determine whether
the device meets the design specifications. If any of the
manufactured devices does not meet design specifications,
then it is rejected for use.
The requirements of meeting regulatory challenges, in-
cluding running large preclinical animal studies, human
clinical trials, and implementing cGMP, is beyond the ca-
pacity of most research laboratories, especially given the
expense (> $5–$10 million for 510K; > $30–$50 million for
IDE/PMA2,3), the need for dedicated manufacturing facilities
and quality systems, and the need to hire dedicated per-
sonnel for regulatory, quality, and manufacturing. Further,
facing the same regulatory and economic challenges, large
established medical device companies are unlikely to invest
the significant amounts of money necessary to bring an
‘‘early stage’’ scaffold technology directly from a university
through to clinical approval. Their preference would be to
invest in a technology where a significant amount of risk has
been addressed, having made it up to or even through phase
I human clinical trials.
The resulting gap between university research and high-
level product development, sales, and marketing is known
as the ‘‘Valley of Death.’’142 In most cases, a third entity,
perhaps analogous to Charon and the river Styx, is needed
to ferry the technology from the research lab to the clinic,
with or without a large medical device industrial partner.
This leaves the choice of a small company, likely a univer-
sity spin-off, to take the technology from a university
research laboratory to 510K approval (including passing
10993 biocompatability tests) and/or up to the start of
phase I human clinical trials. Whether this company exists
or should be created, it will need to secure outside funding
to support product development. Although Small Business
Innovation Research (SBIR) grants can support feasibility
testing, the typical SBIR (between $0.1 and $1 million)
cannot support the sustained drive toward regulatory ap-
proval of a product, especially given the current uncertainty
in federal funding.
Product development by a spin off, therefore, requires
support through venture capital funding. Venture capital
funding, of course, seeks a return on investment (ROI) by
developing a product to potential clinical application (either
510K approval or clinical trials for PMA) and then selling
the spin-off company to a larger medical device company,
or taking the spin-off company public. Maximizing ROI
requires maximizing the potential market for a scaffold
product while minimizing the risk and cost that includes
regulatory approval and subsequent clinical acceptance vis-
a`-vis competing clinical approaches. Both aspects of ROI,
maximizing market while minimizing risk, clearly necessi-
tate defining the specific clinical indication for the scaffold.
Examples include CMF reconstruction, spine fusion, and
segmental long bone defects. Scaffold technologies that re-
quire extensive regulatory approval pathways of 8 years
or more and greater than $100 million will likely need
market value in the multiple hundreds of millions of dollars
to make a venture investment worthwhile. The judgment
to invest can only be made if the clinical indication is
known, as this clinical indication determines the market
size, the regulatory burden, and the competing therapeutic
approaches.
Business challenges to scaffold translation are daunting,
and it is unlikely that they can be completely addressed
within an academic setting. Conversely, due to the financial
risks of bringing multiple new products to the market, large
device companies have a limited bandwidth for developing
new products (especially those requiring a PMA such as
many tissue engineering products), and are likely to rely on
spin-off companies that mitigate a large share of the risk in
getting scaffolds to a 510K approval or into clinical trials for
a PMA. Thus, it is these small, largely spin-off companies
that represent the greatest chance at translation. However,
these companies rely on and collaborate heavily with aca-
demic research laboratories, and a technology cannot be
simply ‘‘thrown over the wall’’ into the spin-off company
through a license agreement. Indeed, initial venture capital
investment may heavily depend on progress toward feasi-
bility in a large preclinical animal model for a clinical indi-
cation, as more translational progress in the academic lab
means a reduced risk for the venture capital investment.
Further, since the spin-off company is on the clock with
venture investment, the sooner it can define the clinical in-
dications, the sooner it can begin regulatory testing and set
up Quality Systems for cGMP. A common temptation for
spin-off companies is to develop a breadth of technologies in
several parallel applications, but this breadth can often be
achieved only at the expense of depth in a focused clinical
indication.
The final business challenge beyond regulatory approval
and the R&D necessary for product development is physi-
cian and hospital acceptance of the scaffold product. Physi-
cian acceptance will depend on how the proposed scaffold or
scaffold/biologic compares with existing clinical approaches,
in most cases bone grafting techniques. Specifically, any new
technology should provide better patient outcomes and/or
be easier or less expensive to use in the operating room.
In summary, business barriers to translation include reg-
ulatory approval, obtaining venture funding on the order of
$1 to $100 million for dedicated product R&D, and attaining
physician acceptance by benchmarking against current clin-
ical approaches. A common thread running through all these
challenges is balancing risk against potential market size.
Use of more complex therapies integrating scaffolds with
biologics may address larger markets and more complicated
defects, but also run higher risk in terms of greater costs for
regulatory approval, larger R&D and quality system costs,
and longer development time.
Here again, a modular approach can mitigate risks in
multiple ways. First, the complexity of a modular system can
be ‘‘dialed in,’’ adjusting its regulatory path. Consider the
most complex of therapies, a combination product consisting
of a scaffold made from a new degradable material directly
coupled with a biologic. This combination product would
face the most difficult class 3 regulatory approval (no matter
what the clinical indication) in addition to satisfying the full
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battery of ISO 10993 biocompatiblity testing, which would
include costly carcinogenic testing. The ISO 10993 tests alone
would likely cost $3–$5 million and take 1–2 years to com-
plete. Another 6–8 years and likely a $50–$100 million in-
vestment would be required to perform the large preclinical
animal testing and human clinical trials for one indication.
This path would likely be complicated by the fact that the
ISO 10993 tests would have to be completed before IRB ap-
proval to begin human clinical trials. This path, of course, is
not only an arduous regulatory path, but also presents sig-
nificant risk to potential investors. If, however, the technology
is modular, then the scaffold technology could be developed
separately from the biologic delivery. For example, the scaf-
fold technology alone could be initially developed as a bone
void filler, with biocompatibility tests and preclinical tests
completed to achieve 510K approval. A product with poten-
tial for at least modest revenue would be in place, biocom-
patibility tests and some preclinical results achieved, to
establish regulatory history. Further, the quality systems
necessary to engineer the scaffold would be in place as re-
quired by the FDA for regulatory approval. Regulatory
complexity of combining the scaffold with the biologic would
be reduced, as biocompatibility tests and some preclinical data
would be on record. Thus, the additional regulatory com-
plexity would involve studying the combination therapy in a
large preclinical model and in human clinical trials. Second,
although additional Quality Systems covering a biologic at-
tachment would be required, Quality Systems governing the
design and manufacturing would be in place. This would
again reduce the investment risk to extend the scaffold
product to a combination product. Third, a modular scaffold
would provide separation of processing steps, thus reducing
investment and maintenance costs as troubleshooting may be
done on isolated modules, which is a significant advantage of
engineering systems using modular approaches.37 In sum-
mary, a modular approach beginning with a scaffold alone or
with surface modified scaffold may achieve approval under a
510K pathway, followed by a scaffold/biologic combination
that would require a PMA. Approval of the scaffold alone
would provide a history of biocompatibility that may aid
additional regulatory applications.
Philosophical Barriers to Scaffold Translation
Addressing the technical and business challenges of scaf-
fold translation requires significant resources and a focus on
specific clinical indications. Whether conscious or not,
translational research targets and the allocation of resources
to meet these targets reflect an underlying philosophy or
model. Two fundamental scientific research models, termed
the ‘‘linear’’ and ‘‘quadrant’’ models, were proposed by Do-
nald Stokes in his book ‘‘Pasteur’s Quadrant: Basic Science
and Technological Innovation.’’143 The linear model (often
ascribed to Vannevar Bush, science advisor to Presidents
Roosevelt and Truman, and father of the National Science
Foundation) proposes a separation of basic and applied re-
search, where basic research is done without regard to final
application, and applied research is done after basic research,
piecing together basic research results to address a problem.
The quadrant approach integrates basic and applied re-
search, with both motivated by a specific problem, and the
drive to solve the problem motivating both applied (near
term) research, and basic research to investigate fundamental
phenomena relative to the defined problem.
How do such models relate to translation of BTE scaffolds?
Implementation of the linear model would proceed from initial
development of a material, to in vitro testing of osteoprogenitor
cells on thematerial, to small animal (mouse and rat) testing, to
large animal testing for specific clinical indications against
competing clinical approaches (e.g., long bone or CMF defects
in sheep, pigs, goats, or non-human primates) to clinical test-
ing. As one proceeds, itwould become necessary to createmore
complex scaffold systems, for example, to withstand the func-
tional loads of preclinical or clinical models, clearly not a ne-
cessity in early cell culture or small animal testing stages.
Clinical indications would not be typically specified until the
preclinical large animal model. In contrast, implementation of
the quadrant model would proceed by first defining a specific
clinical problem (e.g., long bone defect, CMF defect, or spine
fusion), and then developing a modular scaffold system with
defined components (3D material architecture, osteoconduc-
tive interface, and delivered biologics) to test first in the specific
preclinical defect. Difficulties in the large animal system may
lead to further testing and/or screening of basic phenomena in
cell culture or small animal models.
What model prevails in BTE scaffold research and BTE in
general? The closest, as evidenced both by resource alloca-
tion (funded grants) and research targets (percentage of
published papers), is the linear model. However, if the classic
Bush linear model as defined by Stokes was followed, then
one would expect the number of publications on large pre-
clinical animal work for specific defects to increase, and that
funding targeted at specific clinical indications would also be
on the rise. However, examination of both recent funding
and publications indicate that this is not the case. A review of
specific aims and publications from 40 grants funded by the
NIH for BTE (as per the NIH website: http://project
reporter.nih.gov/reporter.cfm; Table 2) in 2010 reveals that
only three grants (7.5%) had aims that utilized animal
models of rabbits or larger and/or had published papers by
using animal models larger than rats (rabbits, dogs, sheep,
pigs, or goats). Estimated funding for these aims totaled
$0.45 million of a total $17.5 million (2.6%).
Beyond the US federal grant support and private in-
vestment, there are in addition, of course, numerous other
national funding agencies in Asia and Europe, including
combined European Union funding for translational re-
search. The European Union has in this sense pursued a
more coordinated effort in translational research under its
Framework Programme (FP) initiatives.144 The recently
completed FP5 initiative funded e66 million (*$93 million)
toward translational research in biomaterials related to
tissue engineering from 2004 to 2007. Within this funding,
e7.3 million ($10.4 million) was used to establish a virtual
European Tissue Engineering Center focused on bone and
cartilage engineering and e2.3 million ($3.3 million) on an
artificial bone graft project. This is roughly an average e3.2
million/year ($4.5 million/year). Although preclinical ani-
mal testing was stated as an outcome of both sub-projects,
the reference did not specify the amount of funds dedicated
to large animal studies. However, given that numerous
other topics were investigated, the amount of funding
dedicated to large preclinical models is likely to be on the
order of, or less than, NIH funding, both in terms of
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absolute funding (likely < $0.5 million/year) and percent-
age of funds.
The final source of translational research funding outside
of public government funding and private investment are
nonprofit foundations. For example, the Wallace H. Coulter
Foundation specifically has a mission of funding transla-
tional research in biomedical engineering that requires a
clinician/researcher investigator team, a definition of clinical
markets, and intellectual property before beginning the re-
search project. In addition, the AO Foundation is another
source of translational research funding, with a particular
focus on musculoskeletal conditions. However, although
foundation funding is a good jumpstart to translational re-
search, funding is by design and necessity (as Foundations
like Coulter fund a large range of biomedical engineering
translational projects and do not focus on tissue engineering)
still aimed at the early research stages, with funds limited to
$0.1 to $1 million per project, on the order of a phase II SBIR
grant. This level of funding cannot sustain the $10–$100’s
millions necessary per product to obtain regulatory ap-
proval.2,3 Instead, such funding levels typically require a
consortium of private investors.
Funding allocation is essentially an ‘‘input metric’’ that
illustrates the motivation for translational research and
development through monetary support. An intermediate
‘‘output metric’’ is peer-reviewed publication. A PubMed
search on the keywords ‘‘bone tissue engineering’’ (BTE) up
to November 2010 revealed a total of 12,219 publications,
whereas a search on ‘‘BTE scaffolds’’ revealed a total of 2268
publications. Of the ‘‘BTE’’ references, only 523 utilized
animals larger than a rat (4.2%), whereas of the ‘‘BTE scaf-
fold’’ references, only 130 utilized animals larger than a rat
(5.7%). If one further categorizes these animal model studies
into large preclinical models for specific clinical indications
that present challenges to bone reconstruction (mandibular
defects (17),97,145–160 long bone defects (14),161–174 cranial
defects (7),175–181 and spine fusion (14)67,182–194) and utilize
BTE in some form (degradable scaffolds with/without bi-
ologics), there have been*52 studies accessible by PubMed
up to 2010. Of these studies, four have acknowledged NIH
support (7.7%), whereas none (0%) acknowledged DOD
support (including AFIRM, which lists significant cranio-
facial and long bone reconstruction as two of its clinical
outcome goals). In comparison, six studies acknowledged
support from local or national funding agencies in China
(11.5%), four studies acknowledged support from local or
national funding agencies in Germany (7.7%), two studies
acknowledged support from local or national funding
agencies each (3.9%) in France, Taiwan, and Singapore, and
one study each (1.9%) acknowledged support from funding
agencies in Switzerland, Sweden, Italy, Japan, and the
Netherlands.
Thus, no matter what metric is applied for either resource
allocation or research targets, research on specific clinical
indications using animal models sufficient to attain regula-
tory approval (510K or PMA) amounted to between 2% and
8% (except for China, with acknowledged funding of over
11.5% of large preclinical studies) of total funding and pub-
lications. Indeed, summing the total number of animals used
in the peer reviewed published large preclinical animal
studies shows that a total of 149 animals were used for long
bong defects, 64 animals for cranial defects, 116 animals for
mandibular defects, and 202 animals for spine fusion. As a
comparison, one PMA study on BMP2 for posteriolateral
lumbar spine fusion used 95 large animals, whereas another
PMA study on BMP2 use for tibial nonunions used 112 large
animals (Table 1). Thus, one FDA study for one clinical
product used the equivalent of 47% to 75% of all the large
animals published in BTE research for the same clinical in-
dication for the past 10 years, of which only 8% were ac-
knowledged and funded by NIH and 0% by the DOD
(including AFIRM, which invested $81 million specifically
for clinical translation) in the United States.
These results clearly indicate that despite the hand
wringing over translation, resource allocation (i.e., grant
funding) and research emphasis (i.e., publications) are not
geared toward translation. An apt analogy is having an
Olympic running team where the stated goal is to win gold
medals in sprints and the marathon. If the only practice time
is spent in running sprints, then no matter how loudly the
coach proclaims that the goal is to win gold medals in both
events, clearly no gold medals will be won in the marathon.
Similarly, no matter how loudly the field proclaims that
translation is the goal, if funding agencies, study sections,
and journals favor scaffold studies in cell culture and small
animal models, but not pre-clinical models targeting relevant
Table 2. Total Amount of National Institutes of Health Funding and Grants Supported
in 2010 for Bone Tissue Engineering
# Grants and funding
per animal model
Institute:
NIDCR
Institute:
NIAMS
Institute:
NIBIB
Study section:
MTE
Study section: other
(OCDS, BTSS, special)
In Vitro, Mouse,
Rat
20.5 Grants,
$9.05M
12 Grants, $5.2M 6 Grants, $2.8M 24.5 Grants, $8.55M 14 Grants, $8.5M
Rabbit 0 Grants, $0 0 Grants, $0 0.5 Grants, $0.1Ma 1.5 Grants, $0.45M
Dog, Pig, Sheep,
Goat, Primate
0.5 Grants,
$0.15Ma
0 Grant, $0 0.5 Grants, $0.2Ma 0.5 Grants, $0.2Ma
Dollar amounts and grants were obtained from the National Institutes of Health website: http://projectreporter.nih.gov/reporter.cfm.
Animal models were determined from the Specific Aims.
Funding for grants in which aims were split into small animal/cell culture, and large animals were double counted as it was not possible to
split costs by aim.
aIndicates that an animal model was proposed, but as of the paper submission, no publication was on PubMed.
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bone defects or clinical trials (as reflected by the roughly 5%
resource allocation for clinically relevant defect studies), then
translation will simply not occur. In looking at the data re-
garding translation, it is clear that the field is not ‘‘putting
our money where our mouth is.’’
Clearly, the current path has inhibited rather than en-
hanced scaffold translation. Although there is a clear and
necessary role for discovery-based basic science in tissue
engineering, there should be a balance between basic science
and translational research and development, which is not
achieved when well more than 90%–95% of resources are
allocated toward discovery research and the rest toward
translation. Here, we define translation as engineering a
scaffold for a specific clinical indication and testing that
scaffold in a large in vivomodel which realistically stimulates
the target human clinical indication. Although some may
argue that it is not the purpose of federal funding to support
translation, translation will not realistically occur without
significant federal support. Others may argue that federal
funds should focus on fostering innovation in the form of
discovery research. However, innovative discoveries are of
limited value if they cannot be used in clinical applications,
and it is clear that substantial innovation is needed to over-
come the hurdles to clinical translation. Given the significant
business barriers, chances of translation increase when
technology coming out of academic laboratories is more
mature, can readily be implemented in quality controlled
scalable processes, and realistically addresses important
specific and, perhaps, multiple clinical indications. In this
path, modularity that supports platform technology pro-
duction is a significant benefit.
The question becomes as to what can be done to improve
federal support of translation. In the current economic cli-
mate, it is unlikely that NIH or other federal funding sources
will increase. Therefore, a conscious decision should be made
to shift a portion of funding to translation focused projects.
Specifically, NIH or other federal agencies should set aside
research money for specific BTE translational projects. This
percentage will likely need to increase to 25%–30% of BTE
funding, compared with the current 2%–8% levels, if in-
creased translation is to be a reality. Increased federal
funding of targeted large preclinical animal models would
encourage private venture funding by reducing regulatory
and market related risk. Specifically, risk would be reduced
by successful demonstration of clinically relevant scaffold
therapies against clinical gold standards in an academic
setting. Such results would demonstrate the capability of
performing necessary preclinical studies as well as demon-
strating that a new technology could compete against a
clinical standard, allowing assessment by, and attracting
interest of, venture funding and large medical device com-
panies.
Projects funded under a translational emphasis, however,
should be clearly defined and more rigorously thought out
than in previous funding efforts. We would suggest that
such projects target a specific clinical indication, and further,
layout out a regulatory approval path, quality systems im-
plementation of the proposed technology, and the potential
market in the proposal. The proposal should delineate where
the proposed work fits in the path. In addition, such pro-
posals should be multidisciplinary, specifically including
clinicians who practice in the clinical indication, and who
would help implement large preclinical animal model test-
ing, another requirement of the project. Some components,
such as detailed regulatory insights and marketing insight/
data, may be difficult to build into translational research
proposals in their formative stages, due to the need for
highly specialized and costly expertise. The need for such
unique resources in all translational research endeavors
perhaps presents an opportunity for funding agencies or
institutions to create core services that provide the needed
expertise.
To help direct such targeted funding, significant input is
needed not only from the research community, but also
from the clinical community, the venture capital commu-
nity, and the corporate medical device community. Having
dedicated workshops where practitioners from each com-
munity come together to draft the requirements for an RFA
is necessary. Specifically, having both clinicians and in-
dustrial partners from CMF, orthopedics, and spine surgery
will be critical.
In conclusion, there are significant barriers that explain the
dearth of scaffold translation. These include the numerous
technical and business barriers (especially definition of and
engineering scaffolds for specific clinical indications) that
present an engineering paradox. Technical barriers to fulfill
the 4Fs push increased scaffold complexity, but business
barriers penalize complexity in terms of increased regulatory
and quality systems cost and implementation time. These
difficulties may be mitigated through engineering modular-
ity, which allows for a sliding scale of complexity. Finally,
however, there are philosophical barriers that cannot be
adequately addressed by individual labs or product devel-
opment teams, but only by the field as a whole if translation
is to be increased. These include, first, recognizing the special
needs of translational science and engineering and, second,
the need to allocate sufficient resources (both funding and
intellectual recognition in terms of publishing) to these
needs.
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